Trial Profile
Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care (PEDAL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Mecasermin rinfabate (Primary)
- Indications Retinopathy of prematurity
- Focus Adverse reactions; Therapeutic Use
- Acronyms PEDAL
- Sponsors Premacure; Shire; Takeda
- 16 Nov 2021 Status changed from active, no longer recruiting to completed.
- 10 Jun 2021 Planned End Date changed from 14 May 2021 to 30 Sep 2021.
- 10 Jun 2021 Planned primary completion date changed from 14 May 2021 to 30 Sep 2021.